{"entity":{"id":"alcestobart","kind":"drug","name":"Alcestobart","aka":["LBL-007"],"tldr":"Alcestobart is an experimental monoclonal antibody from Nanjing Leads Biolabs, in phase 2 trials for nasopharyngeal carcinoma and melanoma.","summary":"Alcestobart (LBL-007) is a monoclonal antibody (fully human IgG4) from Nanjing Leads Biolabs. A fully human IgG4 antibody against LAG-3 that blocks LAG-3 binding to its inhibitory ligands and causes LAG-3 to be taken into the cell, reducing it on the cell surface. Its furthest stage is phase 2, for nasopharyngeal carcinoma and melanoma. ClinicalTrials.gov registers it in 9 studies linked below. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Nanjing Leads Biolabs: leadsbiolabs.com","url":"https://www.leadsbiolabs.com/_nuxt/C0xAGIJr.js"},{"label":"Nanjing Leads Biolabs: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT05609370"},{"label":"ClinicalTrials.gov: trials of LBL-007","url":"https://clinicaltrials.gov/search?intr=LBL-007"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":["lag3"],"drugs":[],"companies":["nanjing-leads-biolabs"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05516914","nct05102006","nct04640545","nct05609370","nct03744468","nct05635708","nct05909904","nct05577702","nct06010303"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"LBL-007","modality":"Monoclonal antibody (fully human IgG4)","mechanism":"A fully human IgG4 antibody against LAG-3 that blocks LAG-3 binding to its inhibitory ligands and causes LAG-3 to be taken into the cell, reducing it on the cell surface.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/alcestobart/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"target":[{"id":"lag3","kind":"target","name":"LAG-3","route":"/targets/lag3/"}],"company":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"}],"trial":[{"id":"nct05102006","kind":"trial","name":"A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors","route":"/trials/nct05102006/"},{"id":"nct05516914","kind":"trial","name":"A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors","route":"/trials/nct05516914/"},{"id":"nct05609370","kind":"trial","name":"A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus ","route":"/trials/nct05609370/"},{"id":"nct05909904","kind":"trial","name":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma","route":"/trials/nct05909904/"},{"id":"nct05635708","kind":"trial","name":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","route":"/trials/nct05635708/"},{"id":"nct04640545","kind":"trial","name":"A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma","route":"/trials/nct04640545/"},{"id":"nct06010303","kind":"trial","name":"A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma","route":"/trials/nct06010303/"},{"id":"nct05577702","kind":"trial","name":"Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer","route":"/trials/nct05577702/"},{"id":"nct03744468","kind":"trial","name":"Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors","route":"/trials/nct03744468/"}]}}